GEHCNasdaqX-Ray Apparatus & Tubes & Related Irradiation ApparatusFiscal year ends December 31
GE HealthCare Technologies Inc.
Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on Jul 29, 2026
$69.76+0.19 (+0.27%)
Close on Oct 19, 2026
- Market cap
- $31.88B
- P/E (TTM)
- 16.7
- Dividend yield
- 0.20%
Margins
Share of revenue, fiscal years 2020 to 2025
Gross margin
40.0%
Operating margin
13.4%
Net margin
10.1%
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +4.8% | +4.0% | – | – | |
| Gross profit | +0.5% | +4.7% | – | – | |
| Operating income | +5.3% | +3.1% | – | – | |
| Net income | +4.6% | +2.8% | – | – | |
| EPS, diluted | +4.8% | +2.5% | – | – | |
| Free cash flow | -3.2% | -6.2% | – | – | |
| Dividend per share | +12.0% | – | – | – |
Returns and balance sheet
6 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2020 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | – | 22.1% | |
| Return on assets | – | – | 6.0% | |
| Current ratio | – | – | 1.37 | |
| Debt to equity | – | – | 1.01 | |
| Inventory turnover | – | – | 5.9× | |
| Capex to revenue | – | – | 2.3% | |
| Diluted shares | – | – | 458M |
Where the cash went
Fiscal 2021 to 2025, five years combined
GE HealthCare Technologies generated $9.78B from operations and spent $2.19B on capital expenditure, dividends and share buybacks. 84% of that went back into the business.
Generated
$9.78B
Used
$2.19B
Capital expenditure$1.83B84%Dividends$160.00M7%Share buybacks$200.00M9%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin10.1%
×Asset turnover0.59×
×Equity multiplier3.72×
=Return on equity, FY202522.1%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 10.1% | 0.59× | 3.72× | 22.1% |
| FY2024 | 10.1% | 0.60× | 4.21× | 25.6% |
| FY2023 | 8.0% | 0.65× | 3.64× | 19.0% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
6of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero$2.08B
- Cash generatingOperating cash flow above zero$1.99B
- Return on assets improvedROA up on the prior year6.1% → 6.3%
- Earnings backed by cashOperating cash flow above net income$1.99B vs $2.08B
- Less leverageLong-term debt to assets fell22.5% → 25.7%
- Better liquidityCurrent ratio rose1.04 → 1.37
- No dilutionShare count did not rise459M → 458M
- Gross margin improvedGross margin up on the prior year41.71% → 39.99%
- More efficientAsset turnover rose0.61 → 0.62